Although this initial study was not intended to measure sensor accuracy, Glucotrack noted that the system performed as expected, delivering results in line with preclinical animal studies. This ...

This milestone study, which aimed to evaluate the safety of the implant, use, and removal of the CBGM sensor lead, confirms the potential of this novel technology. The prospective study was ...

Glucotrack calls its device, which has no external on-body component, a continuous blood glucose monitor (CBGM). The implant is around the length and thickness of three US nickels, with a total ...

(Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Guillermo Umpierrez, MD, CDCES, ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the ...

The company announced the successful completion of its first human clinical trial for its Continuous Blood Glucose Monitor (CBGM), a device that could eliminate both the accuracy limitations of ...

Glucotrack’s Medical Advisory Board provides strategic guidance to Glucotrack as the Company advances development of its innovative CBGM system, which is designed to directly measure blood ...

RUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and ...